Takeno M, Sakane T
Department of Immunology, St. Marianna University School of Medicine.
Nihon Rinsho. 1997 Jun;55(6):1543-8.
Monoclonal antibodies (mAbs) directed to selected cell surface antigens, cytokines and their receptors, and adhesion molecules have been shown to inhibit autoimmune responses in preclinial animal models. Therapeutic trials using the chimeric or humanized mAbs have already been undergoing in patients with rheumatoid arthritis (RA). Effects of anti-CD4 mAb are controversial, but anti-TNF-alpha mAb reveals encouraging results. Although it is too early to determine the efficacy, mAbs are new hopeful therapeutic strategies for autoimmune diseases.
针对特定细胞表面抗原、细胞因子及其受体以及黏附分子的单克隆抗体（mAb）已被证明在临床前动物模型中可抑制自身免疫反应。使用嵌合或人源化单克隆抗体的治疗试验已在类风湿性关节炎（RA）患者中进行。抗CD4单克隆抗体的效果存在争议，但抗TNF-α单克隆抗体显示出令人鼓舞的结果。虽然确定其疗效还为时过早，但单克隆抗体是治疗自身免疫性疾病的新的有希望的治疗策略。
